IMMIX BIOPHARMA, INC. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
IMMIX BIOPHARMA, INC. (IMMX) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $22.75 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was $22.75K, a 54.11% decline year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was -$23.66K, a 243.26% decline year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was -$2.57K, a 103.42% decline year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-06-30 was $49.57K, a 81.19% increase year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was $61.22K.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was -$135.72K, a 384.86% decline from fiscal 2023.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was $47.65K.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2022 was -$38.39K.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.75K 10-Q · filed 2026-08-07 | -$918.00 derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2026-03-31 | -$23.66K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $61.22K 10-K/A · filed 2026-03-27 | |||
| 2025-09-30 | -$2.57K 10-Q · filed 2025-11-07 | $47.00K derived: sum of 2 quarters · filed 2026-08-07 | $63.52K derived: sum of 3 quarters · filed 2026-08-07 | |
| 2025-06-30 | $49.57K 10-Q · filed 2026-08-07 | $66.09K derived: sum of 2 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $16.52K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | -$135.72K 10-K/A · filed 2026-03-27 | |||
| 2024-09-30 | $75.08K 10-Q · filed 2025-11-07 | $102.44K derived: sum of 2 quarters · filed 2025-11-07 | $57.38K derived: sum of 3 quarters · filed 2025-11-07 | |
| 2024-06-30 | $27.36K 10-Q · filed 2025-11-07 | -$17.69K derived: sum of 2 quarters · filed 2025-11-07 | ||
| 2024-03-31 | -$45.05K 10-Q · filed 2025-11-07 | |||
| 2023-12-31 | $47.65K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | -$34.15K 10-Q · filed 2024-11-12 | -$35.81K derived: sum of 2 quarters · filed 2024-11-12 | -$40.29K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$1.67K 10-Q · filed 2024-11-12 | -$6.14K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$4.47K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$38.39K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$40.39K 10-Q · filed 2023-11-13 | -$78.94K derived: sum of 2 quarters · filed 2023-11-13 | -$63.35K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$38.55K 10-Q · filed 2023-11-13 | -$22.96K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $15.59K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | -$6.45K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | -$3.52K 10-Q · filed 2022-11-09 | $1.18K derived: sum of 2 quarters · filed 2022-11-09 | -$7.99K derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $4.70K 10-Q · filed 2022-11-09 | -$4.47K derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | -$9.17K 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $63.64K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |